The clinical manifestation of moderate to severe coronavirus disease 2019 (COVID-19) has parallels to secondary hemophagocytic lymphohistiocytosis (HLH) both clinically and based on molecular inflammatory response. We found no evidence to support the utility of risk-stratifying COVID-19 patients using risk scoring methodology designed for HLH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543356 | PMC |
| http://dx.doi.org/10.1093/cid/ciaa1463 | DOI Listing |
Publication Analysis
Top Keywords
hemophagocytic lymphohistiocytosis
8
coronavirus disease
8
disease 2019
8
assessment hemophagocytic
4
lymphohistiocytosis hscore
4
hscore patients
4
patients coronavirus
4
2019 clinical
4
clinical manifestation
4
manifestation moderate
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!